Sato Ryoju, Arita Machiko, Takahashi Hiroshi, Amano Akihiko, Tanaka Ayaka, Hamakawa Masamitsu, Ishida Tadashi
Department of Respiratory Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama, 710-8602, Japan.
Department of Respiratory Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama, 710-8602, Japan.
Respir Investig. 2025 Sep;63(5):744-748. doi: 10.1016/j.resinv.2025.06.007. Epub 2025 Jun 20.
Pneumothorax is a serious complication in patients with idiopathic pulmonary fibrosis (IPF). This study aimed to clarify the clinical course of and risk factors for pneumothorax in patients with IPF.
This was a retrospective, cohort study of 164 patients with IPF diagnosed based on relevant guideline criteria. The clinical course of patients with pneumothorax was summarized, and risk factors for pneumothorax were assessed using Fine-Gray proportional hazards model analysis with time-dependent covariates.
Of the 164 patients, 30 (18.3 %) developed pneumothorax. Of the 30 patients with pneumothorax, 4 (13.3 %) died in hospital, and the median duration of chest tube insertion was 11 (6-17.5) days. Low body mass index (BMI) and upper lobe pleuroparenchymal thickening on high-resolution computed tomography (HRCT) were significantly associated with pneumothorax onset (hazard ratio [HR] = 0.85 and 2.55; 95 % confidence interval [CI]: 0.73-0.98 and 1.14-5.73; P = 0.031 and 0.023, respectively). In patients who had repeat pulmonary function tests 6-18 months after diagnosis, annual reduction rates of forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) were significantly associated with pneumothorax onset (HR = 0.97 and 0.97; 95 % CI: 0.93-1.00 and 0.94-0.99; P = 0.034 and 0.013, respectively).
Pneumothorax is a serious event having a poor prognosis and requiring long-term treatment in patients with IPF. Low BMI, upper lobe pleuroparenchymal thickening on HRCT, annual FVC reduction rates, and annual DLCO reduction rates are associated with the onset of pneumothorax in patients with IPF.
气胸是特发性肺纤维化(IPF)患者的一种严重并发症。本研究旨在阐明IPF患者气胸的临床病程及危险因素。
这是一项对164例根据相关指南标准诊断为IPF的患者进行的回顾性队列研究。总结了气胸患者的临床病程,并使用含时间相依协变量的Fine-Gray比例风险模型分析评估气胸的危险因素。
164例患者中,30例(18.3%)发生了气胸。在30例气胸患者中,4例(13.3%)在医院死亡,胸腔闭式引流管置入的中位时间为11(6 - 17.5)天。低体重指数(BMI)以及高分辨率计算机断层扫描(HRCT)显示的上叶胸膜实质增厚与气胸发作显著相关(风险比[HR]=0.85和2.55;95%置信区间[CI]:0.73 - 0.98和1.14 - 5.73;P分别为0.031和0.023)。在诊断后6 - 18个月进行重复肺功能测试的患者中,用力肺活量(FVC)和肺一氧化碳弥散量(DLCO)的年降低率与气胸发作显著相关(HR = 0.97和0.97;95% CI:0.93 - 1.00和0.94 - 0.99;P分别为0.034和0.013)。
气胸是IPF患者中一种预后不良且需要长期治疗的严重事件。低BMI、HRCT显示的上叶胸膜实质增厚、FVC年降低率以及DLCO年降低率与IPF患者气胸的发作相关。